Regulation of ABO blood group antigen expression by miR-331-3p and miR-1908-5p during hematopoietic stem cell differentiation.
Base Sequence
Blood Group Antigens
/ genetics
Cell Differentiation
/ genetics
Down-Regulation
/ genetics
Gene Expression Regulation
Genotype
Glycosyltransferases
/ genetics
Hematopoietic Stem Cells
/ cytology
Humans
MicroRNAs
/ genetics
Models, Biological
RNA, Messenger
/ genetics
Sp1 Transcription Factor
/ genetics
ABO blood group
HSC
SP1 transcription factor
glycosyltransferase
miRNA
Journal
Stem cells (Dayton, Ohio)
ISSN: 1549-4918
Titre abrégé: Stem Cells
Pays: England
ID NLM: 9304532
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
07
01
2020
revised:
15
06
2020
accepted:
15
06
2020
pubmed:
6
7
2020
medline:
7
7
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
The ABO blood group system is the most important factor in clinical transfusion medicine and is implicated in a number of human diseases. ABO antigens are not confined to red blood cells (RBCs) and are widely expressed in a variety of human cells and tissues. To date, many alleles with variant ABO expression have been identified and in many cases traced to one of the >250 reported genetic variations in the respective glycosyltransferase. The role of microRNAs (miRNAs) in the regulation of blood group antigens during erythropoiesis has not been addressed, however. Here, we show that miR-331-3p and miR-1908-5p directly target the mRNA of glycosyltransferases A and B. Expression levels of miR-331-3p and miR-1908-5p inversely correlated with levels of blood group A antigen. In addition, we found that overexpression of these miRNAs in hematopoietic stem cells led to a significantly reduced number of blood group A antigens per RBC. Simultaneous targeting of the transcription factor (TF) SP1 by miR-331-3p further enhanced these effects. The targeting rendered SP1 incapable of binding to the ABO gene promoter, causing further downregulation of blood group A antigen expression by up to 70%. Taken together, expression changes in these miRNAs may account for rare cases of weak A/B phenotypes that genetic variations in the glycosyltransferase coding region cannot explain. These results also suggest an explanation for the disappearance of ABH antigens during carcinogenesis and point to new therapeutic targets in ABO mismatched organ transplantation.
Substances chimiques
Blood Group Antigens
0
MIRN1908 microRNA, human
0
MIRN331 microRNA, human
0
MicroRNAs
0
RNA, Messenger
0
Sp1 Transcription Factor
0
Glycosyltransferases
EC 2.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1348-1362Informations de copyright
©2020 The Authors. Stem Cells published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Landsteiner K. Zur Kenntnis der antifermentativen, lytischen und agglutinierenden Wirkungen des Blutserums und der Lymphe. Zentralblatt für Bakteriologie, Parasitenkunde und Infektionskrankheiten. 1900;27:357-362.
Yamamoto F, Clausen H, White T, Marken J, Hakomori SI. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229-233.
Clausen H, White T, Takio K, et al. Isolation to homogeneity and partial characterization of a histo-blood group A defined Fuc alpha 1-2Gal alpha 1-3-N-acetylgalactosaminyltransferase from human lung tissue. J Biol Chem. 1990;265(2):1139-1145.
Anstee DJ. The relationship between blood groups and disease. Blood. 2010;115(23):4635-4643.
Schenkel-Brunner H. ABO(H) System. Human Blood Groups. 2nd ed. New York, NY: Springer-Verlag; 2000:54-150.
Yamamoto F. Review: ABO blood group system-ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes [in English]. Immunohematology. 2004;20(1):3-22.
Takeya A, Hosomi O, Ishiura M. Complete purification and characterization of alpha-3-N-acetylgalactosaminyltransferase encoded by the human blood group A gene [in English]. J Biochem. 1990;107(3):360-368.
Yamamoto F, McNeill PD, Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal [in English]. Biochem Biophys Res Commun. 1992;187(1):366-374.
Hata Y, Kominato Y, Yamamoto FI, Takizawa H. Characterization of the human ABO gene promoter in erythroid cell lineage [in English]. Vox Sang. 2002;82(1):39-46.
Kominato Y, Hata Y, Takizawa H, Tsuchiya T, Tsukada J, Yamamoto FI. Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region [in English]. J Biol Chem. 1999;274(52):37240-37250.
Bianco-Miotto T, Hussey DJ, Day TK, O'Keefe DS, Dobrovic A. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One. 2009;4(3):e4788.
Chihara Y, Sugano K, Kobayashi A, et al. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene [in English]. Lab Invest. 2005;85(7):895-907.
Kominato Y, Tsuchiya T, Hata N, Takizawa H, Yamamoto FI. Transcription of human ABO histo-blood group genes is dependent upon binding of transcription factor CBF/NF-Y to minisatellite sequence [in English]. J Biol Chem. 1997;272(41):25890-25898.
Hata Y, Kominato Y, Takizawa H. Identification and characterization of a novel antisense RNA transcribed from the opposite strand of the human blood group ABO gene. Transfusion. 2007;47(5):842-851.
Yu LC, Chang CY, Twu YC, Lin M. Human histo-blood group ABO glycosyltransferase genes: different enhancer structures with different transcriptional activities [in English]. Biochem Biophys Res Commun. 2000;273(2):459-466.
Thuresson B, Hosseini-Maaf B, Hult AK, Hustinx H, Alan Chester M, Olsson ML. A novel B(weak) hybrid allele lacks three enhancer repeats but generates normal ABO transcript levels [in English]. Vox Sang. 2012;102(1):55-64.
Thuresson B, Chester MA, Storry JR, Olsson ML. ABO transcript levels in peripheral blood and erythropoietic culture show different allele-related patterns independent of the CBF/NF-Y enhancer motif and multiple novel allele-specific variations in the 5′- and 3′-noncoding regions [in English]. Transfusion. 2008;48(3):493-504.
Sano R, Nakajima T, Takahashi K, et al. Expression of ABO blood-group genes is dependent upon an erythroid cell-specific regulatory element that is deleted in persons with the B(m) phenotype [in English]. Blood. 2012;119(22):5301-5310.
Takahashi Y, Isa K, Sano R, et al. Deletion of the RUNX1 binding site in the erythroid cell-specific regulatory element of the ABO gene in two individuals with the Am phenotype [in English]. Vox Sang. 2014;106(2):167-175.
Bianco T, Farmer BJ, Sage RE, Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood. 2001;97(11):3633-3639.
Nambiar RK, Narayanan G, Prakash NP, Vijayalakshmi K. Blood group change in acute myeloid leukemia. Proceedings. 2017;30(1):74-75.
Novaretti MC, Domingues AE, Manhani R, et al. ABO genotyping in leukemia patients reveals new ABO variant alleles. Genet Mol Res. 2008;7(1):87-94.
Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759-774.
Vishnoi A, Rani S. miRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1-10.
Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228-234.
Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation [in English]. Blood. 2006;108(12):3646-3653.
Giarratana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro-generated red blood cells [in English]. Blood. 2011;118(19):5071-5079.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets [in English]. Cell. 2005;120(1):15-20.
Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo [in English]. J Clin Invest. 1991;88(5):1613-1621.
Miller DM, Polansky DA, Thomas SD, et al. Mithramycin selectively inhibits transcription of G-C containing DNA [in English]. Am J Med Sci. 1987;294(5):388-394.
Merika M, Orkin SH. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF [in English]. Mol Cell Biol. 1995;15(5):2437-2447.
Olsson ML, Chester MA. Frequent occurrence of a variant O1 gene at the blood group ABO locus. Vox Sang. 1996;70(1):26-30.
Shimada I, Kominato Y, Hata N, Takizawa H. DNA polymorphisms in the 5′-flanking sequence of human ABO blood group genes and their association with the alleles for the common ABO phenotypes [in English]. Leg Med. 1999;1(4):217-225.
Periyasamy S, Ammanamanchi S, Tillekeratne MP, et al. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency. Oncogene. 2000;19(40):4660-4667.
Zhang L, Song X, Chen X, et al. Circular RNA CircCACTIN promotes gastric cancer progression by sponging MiR-331-3p and regulating TGFBR1 expression. Int J Biol Sci. 2019;15(5):1091-1103.
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484-492.
Tirado-Magallanes R, Rebbani K, Lim R, Pradhan S, Benoukraf T. Whole genome DNA methylation: beyond genes silencing. Oncotarget. 2017;8(3):5629-5637.
Gomes AQ, Nolasco S, Soares H. Non-coding RNAs: multi-tasking molecules in the cell. Int J Mol Sci. 2013;14(8):16010-16039.
Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017;8(5-6):203-212.
Zhang Y, Cheng C, He D, et al. Transcriptional gene silencing of dopamine D3 receptor caused by let-7d mimics in immortalized renal proximal tubule cells of rats. Gene. 2016;580(2):89-95.
Li J, Li S, Liu Q, et al. Effects of ABO and FUT2 genetic transcription absence on ABH histo-blood group antigen expression in lung cancer patients. Asian Pac J Cancer Prev. 2011;12(12):3201-3206.
Matsumoto H, Muramatsu H, Shimotakahara T, et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer. 1993;72(1):75-81.
Miyake M, Taki T, Hitomi S, Hakomori SI. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med. 1992;327(1):14-18.
Orntoft TF, Meldgaard P, Pedersen B, Wolf H. The blood group ABO gene transcript is down-regulated in human bladder tumors and growth-stimulated urothelial cell lines. Cancer Res. 1996;56(5):1031-1036.
Cao Y, Chen J, Wang D, et al. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Oncotarget. 2015;6(35):38093-38106.
Kim HR, Shin CH, Lee H, et al. MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3. Oncotarget. 2017;8(5):8342-8355.
Nymark P, Guled M, Borze I, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer [in English]. Genes Chromosomes Cancer. 2011;50(8):585-597.
Sierzega M, Kaczor M, Kolodziejczyk P, et al. Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331 [in English]. Br J Cancer. 2017;117(2):266-273.
Meldgaard P, Johnson PH, Langkilde NC, Wolf H, Ørntoft TF. Loss of ABH antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus. Int J Cancer. 1995;63(3):341-344.
Van Loghem JJ Jr, Dorfmeier H, Van Der Hart M. Two A antigens with abnormal serologic properties. Vox Sang. 1957;2(1):16-24.